BACKGROUND: The effect of atorvastatin on kidney function was assessed in patients with
stages 2–4 chronic kidney disease. METHODS: We conducted a randomised, double-blind …

Background: The safety and tolerability of rosuvastatin were assessed using data from
16,876 patients who received rosuvastatin 5–40 mg in a multinational phase II/III/IIIb/IV …

Introduction: The prevalence of chronic kidney disease (CKD), a risk factor for
cardiovascular disease (CVD), is increasing worldwide. Statin treatment, the cornerstone of …

Diabetes is the leading cause of chronic kidney disease, which in the Thailand is the most
common cause of end stage renal disease (ESRD) requiring dialysis. Patients with diabetic …

BACKGROUND: Dyslipidemia is common in patients with chronic kidney disease. The role
of statin therapy in the progression of kidney disease is unclear. STUDY DESIGN …

Background: The role of statin therapy in the development of kidney disease in patients with
type 2 diabetes mellitus (DM) remains uncertain. We aimed to determine the relationships …

3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors (statins) are potent
cholesterol-lowering drugs which also possess beneficial antioxidant, antiinflammatory …

Background Fenofibrate has been used for the management of atherogenic dyslipidaemia
for many years. Reports of fenofibrate‐associated increases in serum creatinine (SC r) …

Uncontrolled hypertension is associated with an increased risk of end-stage renal disease
(ESRD). Intensified blood pressure control may slow progression of chronic kidney disease; …

We have developed a re-usable multi-layer microfluidic device to model the human kidney
that incorporates a porous growth substrate, physiological fluid flow, and the passive …